Literature DB >> 19337278

Vasculitis syndromes: vasculitis therapy--between Scylla and Charybdis.

Richard Watts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19337278     DOI： 10.1038/nrrheum.2009.46

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis.

Authors:  Maria Koukoulaki; David R W Jayne
Journal:  Nephron Clin Pract       Date:  2005-11-10

2.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kirsten De Groot; Niels Rasmussen; Paul A Bacon; Jan Willem Cohen Tervaert; Conleth Feighery; Gina Gregorini; Wolfgang L Gross; Raashid Luqmani; David R W Jayne
Journal:  Arthritis Rheum       Date:  2005-08

Review 3.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

4.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

5.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

6.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

7.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.

Authors:  C Metzler; N Miehle; K Manger; C Iking-Konert; K de Groot; B Hellmich; W L Gross; E Reinhold-Keller
Journal:  Rheumatology (Oxford)       Date:  2007-05-22       Impact factor: 7.580

8.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

Review 9.  Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.

Authors:  M Walsh; D Jayne
Journal:  Kidney Int       Date:  2007-07-04       Impact factor: 10.612
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.